home / stock / eols / eols news

EOLS News and Press, Evolus Inc.

Stock Information
Company Name: Evolus Inc.
Stock Symbol: EOLS
Market: NASDAQ
Website: evolus.com
Menu
Get EOLS Alerts

News, Short Squeeze, Breakout and More Instantly...
EOLS - Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau ® and Nuceiva ® across all Evolus commercial markets Further leverages Evolus’ international commercial infrastructure to support long-term profitable growth ...
EOLS - One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics PR Newswire Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met i...

EOLS - Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and comm...

EOLS - A New Copper-Gold Porphyry Target in Southern Ecuador Lands on Salazar Resources' Cornerstone Project Map

2026-05-26 11:18:51 ET Surface mapping at the 100% owned Monja Project defines a 2 km × 1 km mineralized core within a Paleocene-Miocene metallogenic belt — best rock chip sample returns 4.77% Cu, 1.12 g/t Au, 19.5 g/t Ag VANCOUVER, BC, May 26, 2026 — USA News Group N...
EOLS - Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Canada NewsWire Issued on behalf of Conexeu Sciences Inc. Companies mentioned: Conexeu Sciences Inc. (NASDAQ: CNXU), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Evolus, Inc. (NASDAQ...

EOLS - Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New Yo...

EOLS - Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme ® (pronounced “esteem”), its injectable hyaluronic acid (HA) gel collection in Europe,...
EOLS - Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin

2026-05-05 02:14:12 ET More on Evolus Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript Evolus, Inc. 2025 Q4 - Results - Earnings Call Presentation Evolus GAAP EPS of -$0.16 beats by $0.06, revenue of $7...

EOLS - Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

2026-05-05 02:13:25 ET Evolus, Inc. (EOLS) Q1 2026 Earnings Call May 4, 2026 4:30 PM EDT Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Tatjana Mitchell - Chief...

EOLS - Evolus (EOLS) Q1 2026 Earnings Transcript

2026-05-04 17:53:43 ET Image source: The Motley Fool. Monday, May 4, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
Next 10